Review
doi: 10.1016/j.blre.2006.12.001.
Epub 2007 Feb 12.
Farnesyltransferase inihibitors in hematologic malignancies
Affiliations
- PMID: 17293017
- DOI: 10.1016/j.blre.2006.12.001
Item in Clipboard
Review
Farnesyltransferase inihibitors in hematologic malignancies
Blood Rev.
2007 Jul.
Abstract
Farnesyltransferase inhibitors (FTIs) inhibit certain cellular signal transduction pathways, and are being evaluated for activity in hematologic malignancies. Tipifarnib and lonafarnib are orally available FTIs that are active against a variety of targets and inhibit several pathways involved in the pathogenesis of hematologic malignancies. FTIs have demonstrated activity in a variety of hematologic diseases, including acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and multiple myeloma. This article reviews the clinical experience with tipifarnib and lonafarnib in the treatment of hematologic malignancies.
Similar articles
-
Farnesyltransferase inhibitors in myelodysplastic syndrome.Curr Hematol Rep. 2005 May;4(3):186-90. Curr Hematol Rep. 2005. PMID: 15865870 Review.
-
Farnesyltransferase inhibitors in myelodysplastic syndrome.Curr Hematol Malig Rep. 2006 Mar;1(1):20-4. doi: 10.1007/s11899-006-0013-8. Curr Hematol Malig Rep. 2006. PMID: 20425327 Review.
-
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Future Oncol. 2005 Dec;1(6):719-31. doi: 10.2217/14796694.1.6.719. Future Oncol. 2005. PMID: 16556050 Review.
-
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.Clin Adv Hematol Oncol. 2008 Apr;6(4):303-10. Clin Adv Hematol Oncol. 2008. PMID: 18496498 Review.
-
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.Curr Med Chem. 2013;20(38):4888-923. doi: 10.2174/09298673113206660262. Curr Med Chem. 2013. PMID: 24059235 Review.
Cited by
-
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.Haematologica. 2014 Jan;99(1):60-9. doi: 10.3324/haematol.2013.087734. Epub 2013 Aug 30. Haematologica. 2014. PMID: 23996484 Free PMC article.
-
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.Cancer. 2020 Sep 1;126(17):3972-3981. doi: 10.1002/cncr.33036. Epub 2020 Jun 18. Cancer. 2020. PMID: 32557577 Free PMC article. Clinical Trial.
-
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24. Blood. 2009. PMID: 19109557 Free PMC article. Clinical Trial.
-
Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.Mol Cancer. 2008 May 19;7:39. doi: 10.1186/1476-4598-7-39. Mol Cancer. 2008. PMID: 18489761 Free PMC article.
-
Palmitoylation of oncogenic NRAS is essential for leukemogenesis.Blood. 2010 Apr 29;115(17):3598-605. doi: 10.1182/blood-2009-03-213876. Epub 2010 Mar 3. Blood. 2010. PMID: 20200357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
